Clinical Trial Update: A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, tolerability and efficacy of TransCon PTH in adults with hypoparathyroidism has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• TransCon PTH (teriparatide)

Snippet

Sponsor: Ascendis Pharma Bone Diseases A/S | Conditions: Hypoparathyroidism, Endocrine System Diseases | Phase 3 | Status: COMPLETED | Results posted: 2025-02-28